Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are anticipating strong results driven by the strong demand of Lilly's blockbuster medications, particularly the diabetes franchise. However, there are also concerns about potential headwinds from generi